Navigating Liver Cancer: Precision Targeting for Enhanced Treatment Outcomes

Overview

Journal Drug Deliv Transl Res

Publisher Springer

Date 2025 Jan 23

PMID 39847205

Authors

Ankit Jain

Ashwini Kumar Mishra

Pooja Hurkat

Satish Shilpi

Nishi Mody

Sanjay Kumar Jain

Affiliations

Soon will be listed here.

Abstract

Cancer treatments such as surgery and chemotherapy have several limitations, including ineffectiveness against large or persistent tumors, high relapse rates, drug toxicity, and non-specificity of therapy. Researchers are exploring advanced strategies for treating this life-threatening disease to address these challenges. One promising approach is targeted drug delivery using prodrugs or surface modification with receptor-specific moieties for active or passive targeting. While various drug delivery systems have shown potential for reaching hepatic cells, nano-carriers offer significant size, distribution, and targetability advantages. Engineered nanocarriers can be customized to achieve effective and safe targeting of tumors by manipulating physical characteristics such as particle size or attaching receptor-specific ligands. This method is particularly advantageous in treating liver cancer by targeting specific hepatocyte receptors and enzymatic pathways for both passive and active therapeutic strategies. It highlights the epidemiology of liver cancer and provides an in-depth analysis of the various targeting approaches, including prodrugs, liposomes, magneto-liposomes, micelles, glycol-dendrimers, magnetic nanoparticles, chylomicron-based emulsion, and quantum dots surface modification with receptor-specific moieties. The insights from this review can be immensely significant for preclinical and clinical researchers working towards developing effective treatments for liver cancer. By utilizing these novel strategies, we can overcome the limitations of conventional therapies and offer better outcomes for liver cancer patients.

References

Li C, He W . Global prediction of primary liver cancer incidences and mortality in 2040. J Hepatol. 2022; 78(4):e144-e146. DOI: 10.1016/j.jhep.2022.12.002. View

Devarbhavi H, Asrani S, Arab J, Nartey Y, Pose E, Kamath P . Global burden of liver disease: 2023 update. J Hepatol. 2023; 79(2):516-537. DOI: 10.1016/j.jhep.2023.03.017. View

Bray F, Jemal A, Grey N, Ferlay J, Forman D . Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. Lancet Oncol. 2012; 13(8):790-801. DOI: 10.1016/S1470-2045(12)70211-5. View

Yuan L, Wang J, Shen W . Reversible lipidization of somatostatin analogues for the liver targeting. Eur J Pharm Biopharm. 2008; 70(2):615-20. DOI: 10.1016/j.ejpb.2008.05.004. View

Thomas S, Wattenberg M, Choi-Bose S, Uhlik M, Harrison B, Coho H . Kupffer cells prevent pancreatic ductal adenocarcinoma metastasis to the liver in mice. Nat Commun. 2023; 14(1):6330. PMC: 10564762. DOI: 10.1038/s41467-023-41771-z. View

Peng W, Cheng S, Bao Z, Wang Y, Zhou W, Wang J . Advances in the research of nanodrug delivery system for targeted treatment of liver fibrosis. Biomed Pharmacother. 2021; 137:111342. DOI: 10.1016/j.biopha.2021.111342. View

El-Serag H, Marrero J, Rudolph L, Reddy K . Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology. 2008; 134(6):1752-63. DOI: 10.1053/j.gastro.2008.02.090. View

Banerjee S, Singh S, Chowdhury I, Lillard Jr J, Singh R . Combinatorial effect of curcumin with docetaxel modulates apoptotic and cell survival molecules in prostate cancer. Front Biosci (Elite Ed). 2017; 9(2):235-245. PMC: 5545125. DOI: 10.2741/e798. View

Carr B . Some new approaches to the management of hepatocellular carcinoma. Semin Oncol. 2012; 39(4):369-73. DOI: 10.1053/j.seminoncol.2012.05.007. View

10.

Fatouh A, Elshafeey A, Abdelbary A . Galactosylated Chitosan Coated Liposomes of Ledipasvir for Liver Targeting: Chemical Synthesis, Statistical Optimization, In-vitro and In-vivo evaluation. J Pharm Sci. 2020; 110(3):1148-1159. DOI: 10.1016/j.xphs.2020.10.002. View

11.

Wang M, Zhang M, Fu L, Lin J, Zhou X, Zhou P . Liver-targeted delivery of TSG-6 by calcium phosphate nanoparticles for the management of liver fibrosis. Theranostics. 2020; 10(1):36-49. PMC: 6929629. DOI: 10.7150/thno.37301. View

12.

Ahmadian E, Janas D, Eftekhari A, Zare N . Application of carbon nanotubes in sensing/monitoring of pancreas and liver cancer. Chemosphere. 2022; 302:134826. DOI: 10.1016/j.chemosphere.2022.134826. View

13.

Sun L, Fan M, Huang D, Li B, Xu R, Gao F . Clodronate-loaded liposomal and fibroblast-derived exosomal hybrid system for enhanced drug delivery to pulmonary fibrosis. Biomaterials. 2021; 271:120761. DOI: 10.1016/j.biomaterials.2021.120761. View

14.

Yin Q, Tang L, Cai K, Tong R, Sternberg R, Yang X . Pamidronate functionalized nanoconjugates for targeted therapy of focal skeletal malignant osteolysis. Proc Natl Acad Sci U S A. 2016; 113(32):E4601-9. PMC: 4987772. DOI: 10.1073/pnas.1603316113. View

15.

Key J, Palange A, Gentile F, Aryal S, Stigliano C, Di Mascolo D . Soft Discoidal Polymeric Nanoconstructs Resist Macrophage Uptake and Enhance Vascular Targeting in Tumors. ACS Nano. 2015; 9(12):11628-41. DOI: 10.1021/acsnano.5b04866. View

16.

Sharma V, Jain A, Soni V . Nano-aggregates: emerging delivery tools for tumor therapy. Crit Rev Ther Drug Carrier Syst. 2013; 30(6):535-63. DOI: 10.1615/critrevtherdrugcarriersyst.2013007706. View

17.

Gajbhiye K, Chaudhari B, Pokharkar V, Pawar A, Gajbhiye V . Stimuli-responsive biodegradable polyurethane nano-constructs as a potential triggered drug delivery vehicle for cancer therapy. Int J Pharm. 2020; 588:119781. DOI: 10.1016/j.ijpharm.2020.119781. View

18.

Hierro C, Rodon J, Tabernero J . Fibroblast Growth Factor (FGF) Receptor/FGF Inhibitors: Novel Targets and Strategies for Optimization of Response of Solid Tumors. Semin Oncol. 2015; 42(6):801-19. DOI: 10.1053/j.seminoncol.2015.09.027. View

19.

Pircher A, Medinger M, Drevs J . Liver cancer: Targeted future options. World J Hepatol. 2011; 3(2):38-44. PMC: 3060418. DOI: 10.4254/wjh.v3.i2.38. View

20.

Chatterjee R, Mitra A . An overview of effective therapies and recent advances in biomarkers for chronic liver diseases and associated liver cancer. Int Immunopharmacol. 2015; 24(2):335-345. DOI: 10.1016/j.intimp.2014.12.024. View